Topical Antiperspirant for Hand-Foot Syndrome

University of Wisconsin (UW)

Status and phase: Completed; Phase 2

Conditions: Palmar-plantar Erythrodysesthesia

Treatments: Drug: antiperspirant

Study type: Interventional

Funder types: Other

Identifiers

NCT00213993

CC-02308

2002-0487

Details and patient eligibility

About

The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.

Enrollment: 14 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has not previously received a regimen that includes 5-fluorouracil
• > 18 years old
• No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant

Exclusion criteria

• < 18 years of age

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

14 participants in 1 patient group

A

Experimental group

Description:

antiperspirant topically to one foot once daily

Treatment:

Drug: antiperspirant